Effect of Curcumin on Clzheimer's disease: a systematic review / Efeito da Curcumina na doença de Alzheimer: revisão sistemática

Flávia Ivanski, Danillo Barbosa, Monica Beatriz Ferreira, Bruno Bonfim Foresti, Viviane Cristine Ferreira

Abstract


Alzheimer's disease is a neurodegenerative disease characterized by the accumulation of amyloid plaques, tau fibrils and generalized neuroinflammation, which lead to functional and memory impairment. Without treatment, several adjuvants are used, such as curcumin. In this context, the objective of this systematic review was to evaluate the effects of curcumin on Alzheimer's disease. The search for “curcumin” + “alzheimer’s disease” resulted from 354 articles, of which 6 were included in this review. Despite the scarcity of research in humans, curcumin proved to be an excellent adjunct to the treatment of the disease, evidenced by its benefits in memory and cognitive function, given by the reduction of the accumulation of senile plaques. In this context, the physiotherapist has full support in recommending periods of administration, provided that they are in safe doses, in order to minimize neurological deficits in these patients.


Keywords


Alzheimer's disease, Curcumin, memory.

Full Text:

PDF

References


Awasthi, H. et al. Protective effect of curcumin against intracerebral streptozotocin induced impairment in memory and cerebral blood flow. Life sciences. 2010;86:87-94.

Barbosa, P.S., Cotta, M. Psicologia e Musicoterapia no Tratamento de Idosos com Demência de Alzheimer. Revista Brasileira de Ciências da Vida. 2017;5:1-5.

Bassani, T. Effects of curcumin on short-term spatial and recognition memory, adult neurogenesis and neuroinflammation in a streptozotocin-induced rat model of dementia of Alzheimer’s type. Behavioural brain research. 2017; 335: 41-54.

Carvalho, P.D.P., Magalhaes, C.M.C., Pedroso, J.S. Tratamentos não farmacológicos que melhoram a qualidade de vida de idosos com doença de Alzheimer: uma revisão sistemática. J. bras. psiquiatr. 2016; 65:334-339.

Daskalopoulou, C. Physical activity and healthy ageing: A systematic review and meta-analysis of longitudinal cohort studies. Ageing Res Rev. 2017;38:6-17.

Dias, K.S. Aplicações Recentes da Abordagem de Fármacos Multialvo para o Tratamento da Doença de Alzheimer. Revista Virtual de Química. 2015;7: 609-648.

Dohare, P. Dose dependence and therapeutic window for the neuroprotective effects of curcumin in thromboembolic model of rat. Behavioural brain research. 2008;193:289-297.

Feng, H. Curcumin ameliorates insulin signalling pathway in brain of Alzheimer’s disease transgenic mice. International journal of immunopathology and pharmacology. 2016;29:734-741.

Gaudreault, S., Sophie, B., Doris, P.J. Increased caveolin-1 expression in Alzheimer’s disease brain. Neurobiology of aging. 2004;25:753-759.

Kim, H. The significance of frailty in the relationship between socioeconomic status and health-related quality of life in the Korean community-dwelling elderly population: mediation analysis with bootstrapping. Qual Life Res. 2017;1:1-8.

Lao, C.D. Dose escalation of a curcuminoid formulation. BMC Complementary Alternative Medicine. 2006;6:1-10.

Liu, Z, et al., Curcumin attenuates beta-amyloid-induced neuroinflammation via activation of peroxisome proliferator-activated receptor-gamma function in a rat model of Alzheimer's disease. Frontiers in pharmacology. 2016;7:261-8.

Mazon, J.N. The impact of obesity on neurodegenerative diseases. Life Sciences. 2017;182: 22-28.

Menezes, A.P.F. Efeitos da curcumina e do resveratrol em ratos com parkinsonismo experimental induzido por 6-Hidroxidopamina: um estudo comportamental e neuroquímico. Dissertação (mestrado) – Universidade Federal do Ceará, Faculdade de Medicina, Departamento de Medicina Clínica, Programa de Pós-Graduação em Ciências Médicas, Fortaleza, 2012.

Pintão, A.M., Silva, I.F. A verdade sobre o açafrão. In: Workshop Plantas Medicinais e Fitoterapêuticas nos Trópicos. IICT/CCCM. 2008. p. 1-19.

Prince, M. The burden of disease in older people and implications for health policy and practice. The Lancet. 2015;385:549-562.

Prince, M. World Alzheimer report 2016: improving healthcare for people living with dementia: coverage, quality and costs now and in the future. Alzheimer’s Disease International (ADI), London, UK.2016.

Santos, M.A.C. Fitoterapia da doença de Alzheimer. 2016. Tese de Doutorado.

Sietske, A.M. The Past, Present, and Future of Instrumental Activities of Daily Living Assessments in Alzheimer's Disease. Alzheimer's & Dementia. 2016; 12:372-373.

Souza, C.M. Efeito neuroprotetor da curcumina sobre o estresse oxidativo, inflamação, memória e dano neuronal de ratos submetidos à isquemia cerebral transitória. Tese (Doutorado) - Universidade Federal do Ceará. Faculdade de Medicina. Programa de Pós-Graduação em Ciências Médicas, Fortaleza, 2012.

Sueth, S.V. Curcumina, o pó dourado do açafrão-da-terra: introspecções sobre química e atividades biológicas. Química Nova. 2015;38:538-552.

Sun, J. Curcumin decreases hyperphosphorylation of tau by down-regulating caveolin-1/GSK-3β in N2a/APP695swe cells and APP/PS1 double transgenic Alzheimer’s disease mice. The American journal of Chinese medicine. 2017;45:1667-1682.

Sundaram, J.R. Curcumin ameliorates neuroinflammation, neurodegeneration, and memory deficits in p25 transgenic mouse model that bears hallmarks of Alzheimer’s disease. Journal of Alzheimer's Disease. 2017;60:1429-1442.

Tabira, T., Kawamura, N. A Study of a Supplement Containing Huperzine A and Curcumin in Dementia Patients and Individuals with Mild Cognitive Impairment. Journal of Alzheimer's Disease. 2018;1:1-4, 2018.

Thiyagarajan, M., Shama, S.S. Neuroprotective effect of curcumin in middle cerebral artery occlusion induced focal cerebral ischemia in rats. Life sciences. 2004;74: 969-985.

Van H.Z. Caveolin‐1 and‐2 and their relationship to cerebral amyloid angiopathy in Alzheimer's disease. Neuropathology and applied neurobiology. 2007;33:317-327.

Wang, Q. Neuroprotective mechanisms of curcumin against cerebral ischemia‐induced neuronal apoptosis and behavioral deficits. Journal of neuroscience research. 2005;82:138-148.

Winbland, B. Defeating Alzheimer's disease and other dementias: a priority for European science and society. The Lancet Neurology. 2016;15:455-532.

Wollen, K. Alzheimer’s disease: the pros and cons of pharmaceutical, nutritional, botanical, and stimulatory therapies, with a discussion of treatment strategies from the perspective of patients and practitioners. Altern Med Rev. 2010;15:223-44.




DOI: https://doi.org/10.34117/bjdv8n6-257